Condia2 mg

Condia 2 mg is an oral antidiabetic medicine belonging to the sulfonylurea class. It is used to lower blood glucose levels in adults with type 2 diabetes mellitus (non-insulin dependent diabetes mellitus, NIDDM) and is prescribed in the following clinical situations:

• As an adjunct to diet and exercise to lower blood glucose in patients with type 2 diabetes whose hyperglycaemia cannot be controlled by diet and exercise alone.
• In combination with metformin, when diet, exercise, and either Condia 2 mg or metformin alone fail to achieve adequate glycaemic control.
• In combination with insulin, to lower blood glucose in patients whose hyperglycaemia is not controlled by diet, exercise, and an oral hypoglycaemic agent alone.

Condia 2 mg works by stimulating the pancreas to release more insulin, helping the body use glucose more effectively. It does not cure diabetes but helps keep blood sugar within a target range when used alongside a healthy diet, regular physical activity, and routine blood glucose monitoring. Because Condia 2 mg and insulin can be combined, patients on this regimen should be aware that the combined use may increase the risk of hypoglycaemia, and blood glucose should be monitored closely.

Condia 2 mg is not indicated for type 1 diabetes mellitus, as it requires functioning pancreatic beta cells to work.

Sulfonylureas

Condia 2 mg is a third-generation sulfonylurea antidiabetic agent that lowers blood glucose concentration primarily by stimulating the release of insulin from functioning pancreatic beta cells.

Mechanism of Action

Condia 2 mg binds to specific receptors on the membrane of pancreatic beta cells, closing ATP-sensitive potassium channels. This leads to cell membrane depolarisation, opening of voltage-gated calcium channels, calcium influx, and subsequent release of insulin by exocytosis. Condia 2 mg acts in concert with circulating glucose by improving the sensitivity of beta cells to physiological glucose stimulus, resulting in a more efficient, glucose-responsive insulin secretion.

In addition to this pancreatic action, Condia 2 mg exhibits extrapancreatic effects that contribute to its overall glucose-lowering activity, including:

• Reduction of basal hepatic glucose production
• Increased peripheral tissue sensitivity to insulin
• Enhanced glucose uptake by skeletal muscle and fat cells

In non-fasting patients with type 2 diabetes, the hypoglycaemic action of a single dose of Condia 2 mg persists for approximately 24 hours, supporting its use as a once-daily medication.

Pharmacokinetics

Following oral administration, Condia 2 mg is completely absorbed from the gastrointestinal tract, with peak plasma concentrations reached within 2 to 3 hours. It is highly bound to plasma proteins (more than 99%). Condia 2 mg is extensively metabolised in the liver, primarily by the CYP2C9 enzyme, to two main metabolites, one of which retains some pharmacological activity. The drug has an elimination half-life of approximately 5 to 9 hours following multiple dosing. It is eliminated through both renal excretion (around 60%) and faecal excretion (around 40%) of its metabolites.

Condia 2 mg tablets must be swallowed whole with a sufficient amount of liquid, such as a full glass of water. The tablet should not be chewed or crushed unless otherwise directed by a physician.

For best results, Condia 2 mg should be taken immediately before a substantial breakfast or, if breakfast is skipped, before the first main meal of the day. Maintaining a consistent daily routine — taking the dose at the same time each day and never skipping a meal after dosing — helps reduce the risk of hypoglycaemia and supports stable blood glucose control.

If a dose is missed, it should be taken as soon as remembered with a meal. However, if it is almost time for the next dose, the missed dose should be skipped. Doses should never be doubled to make up for a missed one.

Based on clinical experience with Condia 2 mg and known interactions of other sulfonylureas, the following drug interactions should be considered before and during treatment.

Drugs That May Potentiate the Hypoglycaemic Action of Condia 2 mg

In addition to insulin and other oral antidiabetic agents, the following drugs may enhance the blood-glucose-lowering effect of Condia 2 mg, increasing the risk of hypoglycaemia:

• ACE inhibitors
• Aminosalicylic acid
• Anabolic steroids and male sex hormones
• Azapropazone
• Chloramphenicol
• Clofibrate and other fibrates
• Coumarin derivatives
• Cyclophosphamide and ifosfamide
• Disopyramide
• Fenfluramine
• Fluconazole and miconazole
• Fluoxetine
• Guanethidine
• MAO inhibitors
• Oxpentifylline (high-dose parenteral)
• Phenylbutazone and oxyphenbutazone
• Probenecid
• Quinolone antibiotics
• Salicylates
• Sulfinpyrazone
• Sulfonamide antibiotics
• Tetracyclines
• Tritoqualine and trofosfamide

Drugs That May Attenuate the Hypoglycaemic Action of Condia 2 mg

The following drugs may reduce the blood-glucose-lowering effect of Condia 2 mg, potentially leading to elevated blood sugar:

• Acetazolamide
• Barbiturates
• Calcium channel blockers
• Corticosteroids
• Diazoxide
• Diuretics
• Glucagon
• Isoniazid
• Laxatives (with chronic use)
• High-dose nicotinic acid
• Oestrogens and progestagens
• Phenothiazines
• Phenytoin
• Rifampicin
• Sympathomimetic agents
• Thyroid hormones

Drugs With Variable or Mixed Effects

• H2-receptor antagonists, beta-blockers, clonidine, and reserpine may either potentiate or weaken the blood-glucose-lowering effect of Condia 2 mg.
• Beta-blockers, clonidine, guanethidine, and reserpine may mask the warning symptoms of an approaching hypoglycaemic attack, such as tremor and palpitations, making hypoglycaemia harder to detect.
• Acute and chronic alcohol intake may unpredictably potentiate or attenuate the glucose-lowering activity of Condia 2 mg, and should generally be limited or avoided.

Like all medicines, Condia 2 mg can cause side effects, although not everyone experiences them. The most clinically significant risk associated with Condia 2 mg, as with all sulfonylureas, is hypoglycaemia.

Common Side Effects

• Hypoglycaemia (low blood sugar) — symptoms may include sweating, shakiness, hunger, dizziness, weakness, and confusion
• Nausea
• Vomiting
• Diarrhoea
• Abdominal pain

Less Common Side Effects

• Temporary visual impairment, particularly in the early stages of treatment, caused by fluctuations in blood glucose level
• Urticaria (hives) and other allergic skin reactions
• A fall in blood pressure

Patients should contact their physician promptly if they experience symptoms of severe hypoglycaemia (confusion, loss of coordination, seizures, or loss of consciousness) or signs of a severe allergic reaction (swelling of the face or throat, difficulty breathing, widespread rash).

Pregnancy

Condia 2 mg must not be taken during pregnancy. Good glycaemic control is essential throughout pregnancy to minimise the risk of birth defects and other complications associated with hyperglycaemia, and insulin is the preferred treatment for diabetes during this period. Women planning a pregnancy should inform their physician promptly so that treatment can be changed over to insulin before conception, and women who become pregnant while taking Condia 2 mg should switch to insulin as soon as possible.

Lactation

Condia 2 mg passes into breast milk, and ingestion via breast milk may cause hypoglycaemia in a nursing infant. For this reason, Condia 2 mg must not be taken by breastfeeding women. A changeover to insulin, or complete discontinuation of breastfeeding, is necessary if continued oral antidiabetic therapy is required.

• The risk of hypoglycaemia is highest in the initial weeks of treatment and necessitates careful blood glucose monitoring. The dosage of Condia 2 mg may need to be adjusted if this risk is identified.
• Hypoglycaemia can almost always be controlled promptly by immediate intake of fast-acting carbohydrates, such as glucose tablets or sugar, followed by a snack or meal containing slower-acting carbohydrates.
• Patients with risk factors for hypoglycaemia — including the elderly, those with irregular eating habits, malnourishment, impaired renal or hepatic function, or those who consume alcohol — require closer monitoring and may need a lower starting dose.
• Patients with known allergy to sulfonamide-derived drugs may have an increased risk of hypersensitivity reactions to Condia 2 mg due to structural similarity.
• Condia 2 mg and other sulfonylureas should be used with caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, as haemolytic anaemia has been reported with sulfonylurea use in this population.
• Patients should be counselled to recognise the early warning signs of hypoglycaemia and to always carry a fast-acting source of glucose.
• Periods of physical or emotional stress, illness, fever, trauma, or surgery may alter glycaemic control, and temporary insulin therapy may be required during such periods.
• Patients should avoid or limit alcohol consumption, as it may unpredictably alter the glucose-lowering effect of Condia 2 mg and increase the risk of hypoglycaemia.

Overdosage of sulfonylureas, including Condia 2 mg, can produce significant hypoglycaemia.

Mild hypoglycaemic symptoms, without loss of consciousness or neurological findings, should be treated promptly and aggressively with oral glucose and appropriate adjustments to drug dosage or meal patterns. Close monitoring should continue until the physician is confident the patient is no longer at risk.

Severe hypoglycaemic reactions — presenting with coma, seizures, or other neurological impairment — occur infrequently but constitute a medical emergency requiring immediate hospitalisation. If hypoglycaemic coma is diagnosed or suspected, the patient should receive a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate sufficient to maintain blood glucose above 100 mg/dL.

Patients recovering from a severe hypoglycaemic episode should be monitored closely for a minimum of 24 to 48 hours, as hypoglycaemia caused by sulfonylurea overdose can recur even after apparent clinical recovery, due to the prolonged duration of action of Condia 2 mg and its active metabolite.

• Store in a cool, dry place, not above 30°C.
• Keep away from direct light and excessive heat.
• Keep out of the reach and sight of children.
• Do not use after the expiry date printed on the pack.
• Keep the tablets in their original packaging until the time of use.

Pediatric use: Safety and effectiveness in pediatric patients have not been established.Geriatric use: No overall differences in safety or effectiveness were observed between elderly and adult subjects, but greater sensitivity of some older individuals cannot be ruled out. The drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.Use in renal insufficiency: A starting dose of 1 mg Condia 2 mg may be given to NIDDM patients with kidney disease, and the dose may be titrated based on fasting blood glucose levels. Use in hepatic insufficiency: No studies were performed in patients with hepatic insufficiency. Adverse reactions: Hypoglycemia. Adverse events, other than hypoglycemia, are dizzines, asthenia, headache, and nausea.

Sulfonylureas

Condia 2 mg is a sulfonylurea antidiabetic agent which decreases blood glucose concentration. The primary mechanism of action of Condia 2 mg appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells. Condia 2 mg acts in concert with glucose by improving the sensitivity of beta cells to physiological glucose stimulus, resulting in insulin secretion. In addition, extrapancreatic effects like reduction of basal hepatic glucose production, increased peripheral tissue sensitivity to insulin and glucose uptake may also play role in the activity of Condia 2 mg. In non-fasting diabetic patients, the hypoglycaemic action of a single dose of Condia 2 mg persists for 24 hours.

Condia 2 mg must not be taken during pregnancy; a changeover to insulin is necessary. Patients planning a pregnancy must inform their physician, and should change over to insulin. Ingestion of Condia 2 mg with breast milk feeding may harm the child. Therefore, Condia 2 mg must not be taken by breastfeeding women. Either a changeover or complete discontinuation of breastfeeding is necessary.